SCHEMBL16789061

SCHEMBL16789061

CC(C)(C)OC(=O)NC(C(=O)OC1CC2CCC(C1)N2Cc1ccccc1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ CHRM2 P08172 3/20 0.46
▸ CHRM5 P08912 3/20 0.46
▸ CHRM1 P11229 3/20 0.46
▸ CHRM3 P20309 3/20 0.46
▸ HTR2C P28335 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ BLM P54132 2/20 0.46
▸ CHRM4 P08173 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ ADRA1A P35348 1/20 0.46
▸ HRH1 P35367 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ CTSS P25774 1/20 0.46
▸ CTSK P43235 1/20 0.46
▸ SLC22A1 O15245 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8512022 0.88 LMNA (0.60) KMT2ACHRM2CHRM5CHRM1CHRM3
SCHEMBL8512023 0.88 LMNA (0.60) KMT2ACHRM2CHRM5CHRM1CHRM3
SCHEMBL8512028 0.88 LMNA (0.60) KMT2ACHRM2CHRM5CHRM1CHRM3
SCHEMBL19415846 0.88 KMT2A (0.52) KMT2AL3MBTL1CTSSCTSK
SCHEMBL17677464 0.87 CHRNA7 (0.45) KMT2AL3MBTL1CHRM2CHRM5CHRM1
SCHEMBL16789063 0.84 BCHE (0.54) KMT2AL3MBTL1LMNABLMMEN1
SCHEMBL16801840 0.80 CHRM2 (0.52) KMT2AL3MBTL1CHRM2CHRM5CHRM1
SCHEMBL16802186 0.79 CTSK (0.48) CHRM2CHRM5CHRM1CHRM3LMNA
SCHEMBL6347304 0.79 MMP2 (0.53) KMT2ACHRM2CHRM5CHRM1CHRM3
SCHEMBL27770063 0.79 MMP2 (0.53) KMT2ACHRM2CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077385-B1 HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES CHIESI FARM SPA (IT) 2017-10-04 — — EP disclosed
US-9133185-B2 Heteroaryl derivatives CHIESI FARMACEUTICI S.P.A (IT) 2015-09-15 — — US disclosed
US-9133185-B2 Heteroaryl derivatives CHIESI FARMACEUTICI S.P.A (IT) 2015-09-15 — — US disclosed
US-20150158858-A1 HETEROARYL DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-11 — — US disclosed
US-20150158858-A1 HETEROARYL DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158858-A1 HETEROARYL DERIVATIVES PDE4A, PDE4B, PDE3A KMT2A 2493/4885L3MBTL1 2028/4885CHRM2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback